Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031993 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase 2 study of Cervical Squamous Cell Carcinoma and Recurrent Cervical Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT00031993 is a Phase 2 study of Cervical Squamous Cell Carcinoma and Recurrent Cervical Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants, below the 119-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00031993, a Phase 2 study of Cervical Squamous Cell Carcinoma and Recurrent Cervical Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2002-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031993
The ClinicalTrials.gov registry entry for NCT00031993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (57% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cervical Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00031993 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00031993 about?
NCT00031993 is a clinical study titled "Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix". This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
What is the current status of trial NCT00031993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2002-03.
What conditions does trial NCT00031993 study?
This clinical trial studies the following conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer.
What interventions are being tested in trial NCT00031993?
The interventions under investigation include: laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00031993?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031993 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
COMPLETED · Phase 2
-
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 2
-
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
COMPLETED · Phase 2
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
Explore more on PlainTrial
Cervical Squamous Cell Carcinoma
All registered trials for this condition
Recurrent Cervical Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.